Global Diabetes Care Devices Market has been estimated at USD 20.4 Billion in 2019 and is projected to reach USD 27.0 Billion by 2024, at a CAGR of 5.79% during the forecast period from 2019 to 2024.Diabetes is a group of metabolic disorders, chronic condition which is associated with abnormally high level of sugar (glucose) in the blood. The diabetes patient pool is expected to reach 380 million by 2025 because of drastic rise in population, sedentary lifestyle, unhealthy dietary patterns etc.
The market driven by factors like increasing pool of patients suffering from diabetes, more investments in R&D resulting in technological innovations, diabetes diagnosis and treatments with minimally to noninvasive techniques. Furthermore, by increasing awareness, improving diagnosis and treatment rates, a growing need among people for safer, faster and effective methods will lead to increased adoption rates for care devices. However, market is restricted by high cost associated with diagnosis and treatment. Moreover, reimbursement issues and patent expiry are also an issue.
The diabetes care devices offer solution to diabetes patients to manage glucose in blood. Here in with, the diabetes care device market is segmented by device type and by country. By type the market has been segmented in to Diabetes monitoring devices, Insulin delivery Systems and Diabetes Control Solutions. Further, the Diabetes Monitoring Devices market is segmented into Self Blood Glucose Monitoring Devices and CGM Systems. Accordingly, Insulin Delivery Systems is segregated under Insulin Pens, Insulin Pumps, Jet Injectors and Insulin Syringes.
Geographically Global diabetes care devices market has been segmented into North America, Asia-Pacific, Europe, Latin America and Middle-East & Africa. Among these the North America held the largest share in the global diabetes care products market. Europe and Asia-Pacific follows the North America’s way. Especially the Asia-Pacific region provides significant opportunities for the diabetes care in which China (1.3 billion) and India (1.2 billion) being the most populous countries in this region, contributes for the demand for diabetes care devices. According to the International Diabetes Federation, China had the largest number of diabetic patients with around 96.2 million and India had around 66.8 million diabetic patients. As of 2018, approximately 45% of the global diabetic population are from China and India. So many global diabetes care devices companies show interest to invest in these countries.
The market is mainly dominated by Roche Diagnostics with its Accu Chek line of products and followed by different companies like Johnson & Johnson, with its subsidiaries LifeScan, Inc. and Animas Inc. Becton-Dickinson and Novo Nordisk are the two Companies which have been the market leaders in insulin delivery devices market, especially in pens(Insulin) followed by Bayer AG and Abbott Laboratories also has a strong presence in the growing markets for diabetes care devices such as China and India. The other players in the global diabetes care devices market are Ypsomed AG, Medtronic plc, Insulet Inc. Terumo Corporation, Dexcom, Inc. (U.S.), and Tandem Diabetes Care, Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Global Diabetes Care Devices Market, by Type
5.1.1 Glucose Monitoring Devices
5.1.1.1 Self Blood Glucose Monitoring Devices
5.1.1.1.1 Glucose Meters
5.1.1.1.2 Test strips
5.1.1.1.3 Lancets
5.1.1.1.4 Hemoglobin A1C testing Kits
5.1.1.2 Continous Glucose Monitoring Devices
5.1.2 Insulin Delivery Systems
5.1.2.1 Insulin Syringes
5.1.2.2 Insulin Pens
5.1.2.3 Insulin Pumps
5.1.2.4 Jet Injectors
5.1.3 Control Solutions
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.2.7 Switzerland
6.2.8 Russia
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Medtronic Inc.
8.3 Johnson & Johnson
8.4 Abbott Laboratories
8.5 Becton, Dickinson and Company
8.6 Ascensia Diabetes care
8.7 Novo Nordisk A/S
8.8 Dexcom, Inc.
8.9 Insulet Corporation
8.10 Terumo Corporation
8.11 Tandem Diabetes Care, Inc
8.12 Ypsomed AG
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
